Drug updated on 11/13/2023
|Tablet (oral: 2.08 mg)
|Protease-activated receptor-1 (PAR-1) antagonists
| Ongoing and
- Indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).
Product Monograph / Prescribing Information
|Zontivity (vorapaxar) Prescribing Information.
|Xspire Pharmaceuticals LLC, Madison, MS
Systematic Reviews / Meta-Analyses
|Antithrombotic treatments in patients with chronic coronary artery disease or peripheral artery disease: a systematic review of randomised controlled trials.
|Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: a meta-analysis of randomized control trials.
|International Journal of Cardiology
|Vorapaxar for the reduction of thrombotic cardiovascular events in patients With a history of myocardial infarction (MI)